Quoted from http://www.reuters.com/article/rbssHealthcareNews/idUSN2024703020091120
US FDA reviewing Abbott diet drug risks
WASHINGTON, Nov 20 (Reuters) - U.S. regulators are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc's weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug Administration said on Friday.
"The analysis of these data is ongoing and FDA is making no conclusions about the preliminary findings at this time," the agency said in a statement.
The FDA said early findings from a recent study suggested patients taking Meridia may have a higher number of cardiovascular-related problems, including heart attacks, strokes, cardiac arrests and deaths, when compared to patients who took a placebo. (Reporting by Lisa Richwine; editing by Carol Bishopric)